A clinic-based intervention offers safe and effective treatment for high-grade pre-cancerous anal lesions, US investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes.

A large, international clinical trial led by doctors at the University of California, San Francisco indicates that a vaccine to prevent anal cancer is safe and effective, according to a study reported in the Oct. 27, 2011 issue of the New England Journal of Medicine.

 

http://www.ucsf.edu/news/2011/10/10844/clinical-trial-shows-first-evidence-anal-cancer-preventable

Nam have reported on a study in America. Key points:-

• Abnormal anal cells were detected in 53% of patients
• Abnormaility correlates to CD4 count & Viral load
• Abnormaility does not correlate to receptive anal sex

As you can see we desparatly need a volunteer web / graphic designer to jazz up our site and our image.

ScienceDaily (May 9, 2011) — A widely used HIV drug could be used to prevent cervical cancer caused by infection with the human papilloma virus (HPV), say scientists.

ScienceDaily (Apr. 27, 2011) — Human papillomavirus (HPV) causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers. Thanks to research being done at Tufts University School of Medicine, patients infected with cancer-causing HPV may someday have an alternative to surgical and harsh chemical treatments. In a study funded by the National Institutes of Health and published online in advance of print in The FASEB Journal, the researchers report on the development of a protein-based inhibitor that could provide a topical treatment for HPV.

ScienceDaily (Mar. 22, 2011) — A new test for human papillomavirus (HPV) is just as sensitive as the old one, but more specific for detecting cervical cancer, meaning that it has fewer false positive results, according to a paper in the February 2011 Journal of Clinical Microbiology.

ScienceDaily (Feb. 5, 2011) — The vaccine for human papillomavirus (HPV) can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.